Targeting The Paracaspase Malt1: A Potential Therapy To Overcome Ibrutinib Resistance In Relapsed/Refractory Mantle Cell Lymphoma Patients

Changying Jiang,Shengjian Huang,Yang Liu,Carrie Li,Hui Guo,Jeffrey Wang,Elyse Lopez,Hui Zhang,Elizabeth A Lorence,Maria Merolle,Swathi Balaji,Makhdum Ahmed,Krystle Nomie,Xin Lin,Liang Zhang,Michael Wang

BLOOD（2017）

引用 22|浏览17

暂无评分

摘要

Mantle cell lymphoma (MCL) is an aggressive B cell malignancy that is not yet curable. Ibrutinib was approved in 2013 for the treatment of relapsed/refractory MCL patients; however, ibrutinib resistance inevitably develops. Therefore, there is an urgent unmet need to overcome ibrutinib resistance and to study alternative treatment options.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要